Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

36
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
36
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K
Antimicrobial Proteins01:23

Antimicrobial Proteins

15.5K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
15.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.6K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choline-dependent methionine metabolism supports leukemia progression.

Communications biology·2026
Same author

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026
Same author

Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.

Leukemia·2026
Same author

Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myeloma.

Cell death & disease·2026
Same author

On-Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients.

Magnetic resonance in medicine·2026
Same author

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Leukemia·2026

Related Experiment Video

Updated: Apr 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

The interferon-alpha revival in CML.

Moshe Talpaz1, Jessica Mercer, Rüdiger Hehlmann

  • 1Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Comprehensive Cancer Center Room 4302, Ann Arbor, MI, 48109-5936, USA, mtalpaz@umich.edu.

Annals of Hematology
|March 28, 2015
PubMed
Summary
This summary is machine-generated.

Interferon-alpha (IFNα) offers unique benefits for chronic myeloid leukemia (CML) by targeting CML stem cells. Research explores its combination with tyrosine kinase inhibitors (TKIs) to improve CML treatment outcomes.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.7K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.5K

Related Experiment Videos

Last Updated: Apr 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.7K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.5K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Interferon-alpha (IFNα) was a primary treatment for chronic myeloid leukemia (CML).
  • IFNα acts through immune activation and targeting CML stem cells, leading to stable remissions.
  • BCR-ABL tyrosine kinase inhibitors (TKIs) are now standard CML therapy but do not eradicate CML stem cells.

Purpose of the Study:

  • To review the role of IFNα in CML treatment.
  • To explore the potential of combining IFNα with TKIs like imatinib.
  • To identify the optimal use of IFNα in modern CML therapy.

Main Methods:

  • Review of historical and current clinical trial data.
  • Analysis of IFNα's mechanisms of action in CML.
  • Evaluation of combination therapy outcomes and side effects.

Main Results:

  • IFNα can induce long-term, stable CML remissions, with some patients maintaining remission post-therapy.
  • Combination therapy with IFNα and imatinib may accelerate and enhance responses.
  • IFNα's side effects pose challenges, and its optimal therapeutic window remains undefined.

Conclusions:

  • IFNα possesses unique anti-leukemic properties, particularly against CML stem cells.
  • Further research is required to define the precise role and optimal application of IFNα in combination CML treatment strategies.